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In this issue of Immunity, Liao et al. (2013) utilize monoclonal antibodies isolated from RV144 vaccinees to
gain key insights into the structural vulnerabilities of the V1-V2 loops of HIV gp120 protein and how theymight
be associated with vaccine efficacy.The RV144 trial, which consisted of canar-
ypox viral vector (ALVAC) as the prime
and clade B and E gp120 (AIDSVAX B/E)
as the boost and which was conducted
in a low-risk Thai population, demon-
strated modest efficacy (31.2%) (Rerks-
Ngarm et al., 2009). However, it remains
a source of controversy largely because
the vaccine did not induce the broadly
neutralizing antibodies or strong T cell
responses thought to be necessary for
protection. Instead, initial studies gener-
ated the hypothesis that nonneutralizing
antibodies might have provided pro-
tection. Moreover, correlates analysis
(Haynes et al., 2012a) pointed to an asso-
ciation between antibodies against the
V1-V2 loops of gp120 and decreased
risk of infection, further supported by viral
sieve analyses, in which vaccination
altered the likelihood of infection with
specific viral variants within the V2 loop
(Rolland et al., 2012).
Liao et al. demonstrate that vaccine-
induced antibodies can recognize the
V1-V2 loop in dramatically different
conformations (Figure 1), providing data
that pertain to three widely debated ques-
tions in HIV-vaccine research: What can
we learn from RV144? What can we
learn about vaccine-mediated protection
from studies of monoclonal antibodies
(mAbs)? Do vaccines targeting variable
regions of HIV, such as the V2 loop, hold
promise?
Despite conventional wisdom that vari-
able regions make poor vaccine targets,
there is a substantial body of literature
describing the critical nature of the V2
loop (Zolla-Pazner and Cardozo, 2010).
Importantly, transmitted viral variants
exhibit shorter V1-V2 loops containing
fewer N-glycosylation sites (Sagar et al.,8 Immunity 38, January 24, 2013 ª2013 Elsev2006), reflecting an advantage of short
loops in early infection and subsequent
elongation and glycosylation driven by
viral evasion of intense immune pressure
mediated by autologous antibodies
(Rong et al., 2009; Sagar et al., 2006).
Furthermore, V2 antibodies display immu-
nologic cross-reactivity, suggesting that
the V2 region contains conserved three-
dimensional elements (Zolla-Pazner and
Cardozo, 2010).
To probe the characteristics of RV144-
vaccine-induced antibodies, Liao et al.
cloned and crystallized V2-specific
mAbs and linked these mAbs to popula-
tion analyses to determine the profile
and the predominance of particular
patterns of reactivity among vaccinees.
Together, these studies offer critical
insights into loop-recognition patterns
associated with vaccine protection but
also raise questions related to the mecha-
nism by which vaccines might elicit anti-
bodies that target the most vulnerable,
common, or relevant conformations of
flexible and sequence-variable loops.
Despite the sequence variability in the
V2 loop, V2 antibodies can be broadly
cross-reactive and can recognize V2
epitopes in different conformations. As
salient examples, CH58 and CH59,
cloned by Liao et al., bind to linear V2
peptides and therebymark a class of anti-
bodies that react primarily with peptides,
distinct from previously defined confor-
mation-specific 697D-like mAbs and the
glycopeptide, quaternary-specific PG9-
like mAbs. According to their crystal
structures, CH58, CH59, and PG9 recog-
nize overlapping V2 epitopes in remark-
ably different conformations, ranging
from helical to beta strand, begging the
question as to whether the protectiveier Inc.breadth of these V2-specific antibodies
might relate to the ability of V2 to adopt
these different conformations in the con-
text of different envelopes and whether
particular V2-specific antibodies might
lock the V2 loop into conformations that
inhibit or mark the virus more effectively.
Interestingly, CH58 and CH59 interact
differentially with prime and boost enve-
lopes despite identical V1-V2 sequences
between positions 165 and 184, further
supporting the notion that conformation
plays a prominent role in determining
V2-loop immunogenicity, antigenicity,
and possibly sensitivity. Alternatively,
differential recognition of prime and boost
envelopes might also be due to altered
presentation. Conformation and flexibility
differences due to in vivo production and
cell-surface-tethered exposure might
have allowed the prime antigen to adopt
specific shapes, permitting the induction
of CH58- and CH59-like antibodies.
Investigating whether similar antibodies
are inducible by protein vaccination
would help define whether V2 antibodies
are preferentially elicited in different con-
texts. Because sequence alone does not
provide a clear indication of envelope
vulnerabilities, Liao et al. evoke the possi-
bility that understanding V2 shape and
conformational plasticity might provide
critical information for the rational design
of promising immunogens.
The observation that some HIV-specific
antibodies exhibit limited germline diver-
sity, implying that only a restricted set of
suitable naive variable gene segments
exist, has motivated the design of vaccine
regimens that drive B cell evolution along
certain lineages (Haynes et al., 2012b). In-
deed, previous studies of conformation-
dependent V2-specific mAbs suggested
Figure 1. Multiple Roads to Recognition of
the V2 Loop on the HIV gp120 Protein
Remarkably diverse conformations of V2 loop
(indicated by colored shapes) can be recognized
by antibodies. Understanding whether the most
vulnerable, common, or relevant conformations of
sequence-variable loops represent themost prom-
ising immunogensmight be an important avenue of
investigation in rational vaccine design.
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Previewsthat they arise predominantly from the
VH1-69 family (Gorny et al., 2012).
However, perhaps unsurprisingly given
their recognition of dramatically different
V2-peptide conformations, CH58 and
CH59 descended from different VH fami-
lies. Given the diversity of germlines
used and the divergent structures
assumed by V2 peptides, these data are
consistent with the notion that there are
many paths to V2 recognition (Figure 1).
Moreover, the ability of the CH58 and
CH59 unmutated ancestors (UAs) to
bind to the same envelopes from two
different clades, in conjunction with the
remarkably disparate reactivity of UAs of
other V2 antibodies (PG9 and 697D),again supports the argument that in the
case of V2-reactive antibodies, limited
germlines do not appear to dominate,
and understanding structural features of
V2 variants might leverage the germline
repertoire more effectively.
Therefore, despite the controversy
associated with RV144, the substantial
data implicating the importance of the
variable loops in transmission, their
involvement in immune evasion, their tar-
geting by highly cross-reactive antibodies
that reduce infection (Karasavvas et al.,
2012), and their ability to mediate bio-
logic functions including neutralization
and antibody-dependent cell-mediated
cytotoxicity (Gorny et al., 2012), provide
a strong impetus for defining the critical
nature of this viral determinant in antiviral
immunity. Consequently, studies such as
that of Liao et al., using vaccine-induced
mAbs to map structural features of this
vulnerable variable loop, become more
powerful and relevant to vaccination
when paired with broader population
analyses in that they provide a measure
of confidence that eliciting similar anti-
bodies in different subjects is feasible.
Continued study of V2 antibodies and
others with restricted but definitively
protective activity might lead to the
understanding of the structural features
that prompt strain-specific immunity.
Such studies could indicate whether
these protective antibodies are reactive
with conformations shared by most
strains or with immunologically-defined
subtypes of HIV-1, requiring a finite
number of vaccine constructs, analogous
to polio and influenza vaccines. Accord-
ingly, Liao et al., offer hope, but they
also point to significant hurdles encoun-Immunitytered in targeting a sequence- and struc-
turally-variable domain. The biggest
impact of this and similar studies might
be that sequence diversity and limited
crystal structures do not prevent a region
from being a valuable target for a protec-
tive vaccine.
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